REFERENCES
[1] David C, Fajgenbaum D C, Carl H, et al. Cytokine Storm. New
England Journal of Medicine, 2020;383: 2255-2273.
[2] Yu X J, Liang M F, Zhang S Y, et al. Fever with thrombocytopenia
associated with a novel. bunyavirus in China. New England Journal of
Medicine, 2011, 364(16): 1523-1532.
[3] Li H, Lu Q B, Xing B, et al. Epidemiological and Clinical
Features of Laboratory-Diagnosed Severe Fever With Thrombocytopenia
Syndrome in China, 2011-17: A Prospective Observational Study. Lancet
Infectious Diseases, 2018;18: 30293-30297.
[4] Huang C, Wang Y, Li X, et al. Clinical features of patients
infected with 2019 novel. coronavirus in Wuhan, China. Lancet,
2020;15;395(10223): 497-506. (2)
[5] de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human
influenza A (H5N1) is associated with high viral load and
hypercytokinemia.
Nature
Medicine, 2006;12: 1203-1207.
[6] Sefik E, Qu R, Junqueira C, et al. Inflammasome activation in
infected macrophages drives COVID-19 pathology. Nature, 2022;606:
585-593.
[7] Yoo JR, Kim TJ, Heo ST, et al. IL-6 and IL-10 Levels, Rather
Than Viral Load and. Neutralizing Antibody Titers, Determine the Fate of
Patients With Severe Fever With Thrombocytopenia Syndrome Virus
Infection in South Korea. Frontiers in Immunology, 2021;12: 711847.